EGFR Fusion

CI-VAR-00001338Explore in graph →CIViC 4251

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood Ependymoma1
SEC61G::EGFR Fusion	Gefitinib	Predictive	A	Supports Sensitivity Response	1	submitted	EID10933 SEC61G::EGFR (5'UTR::e14) (5'-UTR of SEC61G and 3'-UTR of EGFR) was detected in ependymoma as a change sensitive to gefitinib (also confirmed by mice xenografts model). Screening of 16 ependymoma pati… (full text at CIViC) PMID 29092923 · Servidei et al., 2017 · Open in CIViC	civic
Glioblastoma2
SEC61G::EGFR Fusion	(oncogenic)	Oncogenic	D	Supports Oncogenicity	1	submitted	EID10934 SEC61G::EGFR fusion identified in 4 out of 164 (2.4%) glioblastoma tumors (TCGA GBM working group, patient samples with pathobiology data). Fusion transcripts were confirmed by RNA-seq and were freque… (full text at CIViC) PMID 24120142 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Lung Adenocarcinoma1
SEC61G::EGFR Fusion	Cetuximab + GefitinibCombination	Predictive	C	Supports Sensitivity Response	1	submitted	EID10899 Case report describing a patient with NSCLC and EGFR(ex25)::Intergenic Region of SEC61G(breakpoint 32 aa downstream of SEC61G) fusion and concurrent EGFR amplification with treatment response to a com… (full text at CIViC) PMID 34342091 · Zhang et al., 2021 · Open in CIViC	civic